Bardia A, Neven P, Streich G, et al Elacestrant, an oral selective estrogen receptor degrader vs investigator s choice of endocrine monotherapy for ER HER2 advanced metastatic breast cancer following progression on prior endocrine and CDK4 6 inhibitor therapy Results of EMERALD phase 3 trial allergic to augmentin